title: Identification of an inducible factor secreted by pancreatic cancer cell lines that stimulates the production of fucosylated haptoglobin in hepatoma cells.
abstract: Fucosylation is one of the most important oligosaccharide modifications and is involved in cancer and inflammation. Recently, fucosylated haptoglobin was identified as a possible tumor marker for pancreatic cancer. The molecular mechanism underlying increases in fucosylated haptoglobin in sera of patients with pancreatic cancer seems to be complicated. Our previous study [N. Okuyama, Y. Ide, M. Nakano, T. Nakagawa, K. Yamanaka, K. Moriwaki, K. Murata, H. Ohigashi, S. Yokoyama, H. Eguchi, O. Ishikawa, T. Ito, M. Kato, A. Kasahara, S. Kawano, J. Gu, N. Taniguchi, E. Miyoshi, Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation, Int. J. Cancer 118 (11) (2006) 2803-2808] demonstrated that pancreatic cancer cells secrete a factor, which induces the production of haptoglobin in hepatoma cells. In the present study, we found that interleukin 6 (IL6) expressed in pancreatic cancer is a factor that induces the haptoglobin production, using a neutralizing antibody for IL6. Real-time PCR analyses revealed the up-regulation of fucosylation regulatory genes after IL6 treatment, resulting increases in fucosylated haptoglobin being revealed by a lectin ELISA. This pathway could be one of the possible mechanisms underlying increases in haptoglobin in sera of patients with pancreatic cancer.
authors.affiliation: Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, 1-7 Yamada-oka, Suita 565-0871, Japan.
authors.forename: Megumi
authors.initials: M
authors.lastname: Narisada
authors.forename: Sayuri
authors.initials: S
authors.lastname: Kawamoto
authors.forename: Kana
authors.initials: K
authors.lastname: Kuwamoto
authors.forename: Kenta
authors.initials: K
authors.lastname: Moriwaki
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Nakagawa
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Matsumoto
authors.forename: Michio
authors.initials: M
authors.lastname: Asahi
authors.forename: Nobuto
authors.initials: N
authors.lastname: Koyama
authors.forename: Eiji
authors.initials: E
authors.lastname: Miyoshi
mesh_terms: D000906:Antibodies / Q000494:pharmacology; D006528:Carcinoma, Hepatocellular / Q000378:metabolism*; D045744:Cell Line, Tumor; D017077:Culture Media, Conditioned / Q000494:pharmacology; D005643:Fucose / Q000378:metabolism*; D005647:Fucosyltransferases / Q000235:genetics; D015870:Gene Expression; D006242:Haptoglobins / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000378:metabolism; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism* / Q000494:pharmacology; D008113:Liver Neoplasms / Q000378:metabolism*; D010190:Pancreatic Neoplasms / Q000378:metabolism*; D011499:Protein Processing, Post-Translational / Q000235:genetics; D000093242:Interleukin-6 Inhibitors
chemical_list: D000906:Antibodies; D017077:Culture Media, Conditioned; D005643:Fucose; D005647:Fucosyltransferases; D006242:Haptoglobins; D015850:Interleukin-6; D000093242:Interleukin-6 Inhibitors; C485359:HP protein, human